查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950477

鐮狀細胞疾病基因治療市場按治療模式、改良技術、嚴重程度、支付方類別、患者年齡和分銷管道分類，全球預測，2026-2032年

Gene Therapy for Sickle Cell Disease Market by Treatment Model, Modification Technology, Severity, Payer Category, Patient Age, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鐮狀細胞疾病基因治療市場規模將達到 21.5 億美元，到 2026 年將達到 24.9 億美元。預計到 2032 年，該市場規模將達到 52.5 億美元，年複合成長率為 13.60%。

關鍵市場統計數據
基準年 2025 21.5億美元
預計年份：2026年 24.9億美元
預測年份 2032 52.5億美元
複合年成長率 (%) 13.60%

鐮狀細胞疾病基因療法的現代治療格局，以及科學知識、醫療服務和政策之間的相互作用如何影響其應用。

鐮狀細胞疾病正處於關鍵的轉折點，數十年的臨床觀察與精準基因介入在此交匯。近年來，科學進步、監管里程碑以及日益成熟的臨床計畫共同推動了治療理念從症狀管理轉向持久的緩解疾病。在此背景下，相關人員正在重新調整工作重點，以滿足持續存在的未滿足需求，同時應對根治性治療技術所特有的複雜安全性、生產和可及性挑戰。

近期技術進步、監管政策明朗化以及整合醫學創新如何推動鐮狀細胞疾病治療從症狀治療轉向持久的基因改造

鐮狀細胞疾病治療格局正從漸進式的症狀治療轉向具有變革意義的基因干預，這些干預措施有望重塑長期的臨床預期。基因編輯精準性、載體設計和預處理方案的進步正在降低傳統的療效和安全性障礙，促使研發重點和治療模式進行重新調整。同時，細胞生產物流的改進和分散式治療路徑的建立，正在催生新的治療方法，這些方法在提高患者容量的同時，也能維持嚴格的品管。

評估2025年關稅變化對基因治療跨境採購、生產韌性和專案連續性的實際和策略影響

2025年推出的政策變化和關稅調整，為包括基因治療試劑和細胞處理設備在內的先進生物製藥產品的跨境採購和供應鏈規劃帶來了新的複雜性。這些貿易措施正在影響依賴全球採購載體、試劑和特殊耗材的製造商的成本結構和物流計算。因此，各公司正在重新評估其供應鏈冗餘和近岸外包策略，以確保專案進度和品管。

基於深度細分的指導將治療模式、編輯平台、患者群體、疾病嚴重程度、支付方組成和交付管道與商業化策略聯繫起來。

細分分析為療法研發者和醫療保健系統提供了一個多維觀點，幫助他們確定投資優先順序並設計差異化的價值提案。基於治療模式的「異基因」和「自體」二分法揭示了生產複雜性、預處理要求以及供體選擇和個體化細胞處理的物流方面的差異。基於基因修飾技術，鹼基編輯、CRISPR/Cas9、慢病毒載體和鋅指核酸酶之間的差異會影響關於精準性、脫靶風險以及針對特定載體或編輯平台的品管需求的討論。基於患者年齡，成人和兒童族群在預處理耐受性、長期安全性監測以及早期療育的倫理要求方面存在不同的考慮因素。基於疾病嚴重程度，針對中度疾病和重症疾病的治療方案必須平衡風險接受度和潛在臨床效益，以確定合格標準和試驗終點。基於支付方類型，政府、自費和私人支付方之間的動態會影響報銷途徑、預核准通訊協定和可負擔性計畫。根據通路，透過醫院和專科護理中心進行交付會影響資格認證、跨專業護理的協調以及中心如何收集長期結果數據。

區域比較和基礎設施現狀將影響全球臨床應用、報銷和交付模式。

區域趨勢將顯著影響鐮狀細胞疾病基因療法的臨床和商業性軌跡，每個主要區域的監管環境、基礎設施和支付方考量各不相同。在美洲，成熟的醫療卓越中心和活躍的患者權益倡導組織為早期臨床應用創造了有利條件，而分散的支付方格局則需要量身定做的報銷策略和多方價值提案。在歐洲、中東和非洲地區，監管和交付環境的異質性——集中的監管結構和多樣化的國家支付體系——有利於適應性市場進入模式和區域性生產夥伴關係。在亞太地區，臨床試驗能力的快速成長、對細胞和基因療法生產投資的不斷增加以及不同程度的報銷體系成熟度，都要求制定分階段的、針對特定區域的商業化計劃。

繪製領先的開發商、製造合作夥伴和服務供應商的策略行動圖，這些行動將科學差異化與規模化和與支付方的合作相結合。

企業策略展現出多元化的發展路徑，開發商和服務供應商正努力將科學與商業執行結合。一些領先的生物技術公司和成熟的細胞療法生產商正採取差異化發展路徑，專注於特定的基因編輯平台、載體技術或同種異體移植生產，以解決擴充性和可重複性問題。另一些公司則專注於臨床項目，優先考慮兒童適應症或嚴重表現型，因為這些領域潛在的顯著臨床效益能夠增強其獲得醫保報銷的必要性。

為贊助商和醫療系統領導者提供切實可行的策略步驟，以確保臨床成功、營運韌性以及支付方為永續基因治療做好準備的證據。

產業領導者應採取多管齊下的策略，平衡近期臨床實施與可擴展營運和支付方證據累積的投資。首先，在研究設計中優先考慮穩健的安全性和持久性終點，並擴大註冊登記參與範圍，以確保收集能夠解決支付方和監管機構擔憂的縱向資料。同時，加強與專業治療中心和區域生產合作夥伴的協作，並建立冗餘、品質有保障的供應鏈，以降低跨境中斷和關稅相關風險。

調查方法的透明度：說明了專家訪談、臨床和監管文件的綜合分析以及用於得出具有實際操作意義的研究結果的三角驗證證據。

我們的研究途徑結合了定性和定量技術，對臨床、營運和政策方面進行了嚴謹的分析。主要研究包括對臨床研究人員、治療中心管理人員、監管顧問和支付方代表進行結構化訪談，以了解實際運作中的限制和決策標準。二級資訊來源包括同行評審文獻、clinicaltrials.gov 註冊資訊、監管指導文件和行業白皮書，以闡明臨床終點、安全訊號和監管先例的背景。

一篇綜述重點闡述了科學進步、作戰準備和多方相關人員證據生成之間的相互作用，這些對於持續的治療效果至關重要。

鐮狀細胞疾病基因療法正逐步邁向技術可行性、臨床前景和系統層面準備好三者融合，最終為患者帶來顯著獲益的階段。儘管科學創新已克服了一些歷史遺留的技術障礙，但實際的成功仍取決於各方在提升生產能力、加強臨床醫生培訓、與支付方合作以及了解長期療效等方面的共同投入。積極應對這些營運和證據方面的迫切需求的相關人員，將找到實現持續臨床影響和負責任的商業化的最直接途徑。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章鐮狀細胞疾病基因治療市場（依治療模式分類）

  • 同種異體移植
  • 自體移植

第9章鐮狀細胞疾病基因治療市場（依修飾技術分類）

  • 基礎編輯
  • CRISPR/Cas9
  • 慢病毒載體
  • 鋅指核酸酶

第10章 依嚴重程度分類的鐮狀細胞疾病基因治療市場

  • 緩和
  • 嚴重

第11章鐮狀細胞疾病基因治療市場（依支付方分類）

  • 政府
  • 自費
  • 私人的

第12章鐮狀細胞疾病基因治療市場（依患者年齡分類）

  • 成人
  • 兒童

第13章鐮狀細胞疾病基因治療市場（依通路分類）

  • 醫院
  • 專業治療中心

第14章鐮狀細胞疾病基因治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章鐮狀細胞疾病基因治療市場（依族群分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國鐮狀細胞疾病基因治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國：鐮狀細胞疾病基因治療市場

18. 中國：鐮狀細胞疾病基因治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics, Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • EditForce, Inc.
  • Emmaus Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulcrum Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • Graphite Bio, Inc.
  • Homology Medicines, Inc.
  • Imara, Inc.
  • Incyte Corporation
  • Intellia Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Magenta Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Vertex Pharmaceuticals Incorporated
  • Vifor Pharma AG
Product Code: MRR-4F7A6D4FD88C

The Gene Therapy for Sickle Cell Disease Market was valued at USD 2.15 billion in 2025 and is projected to grow to USD 2.49 billion in 2026, with a CAGR of 13.60%, reaching USD 5.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.15 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 5.25 billion
CAGR (%) 13.60%

Framing the contemporary therapeutic landscape for sickle cell disease gene therapies and the interplay of science, care delivery, and policy influencing adoption

Sickle cell disease stands at an inflection point where decades of clinical observation intersect with precision genetic interventions. The last several years have produced a convergence of scientific advances, regulatory milestones, and clinical program maturation that together are transforming the therapeutic conversation from symptom management to durable disease modification. Against this backdrop, stakeholders across biopharma, clinical practice, and payer communities are recalibrating priorities to address long-standing unmet needs while navigating the complex safety, manufacturing, and access challenges unique to curative-intent technologies.

This report opens with a concise orientation to the biological rationale for gene-based approaches and the contemporary clinical evidence that supports their use in severe phenotypes. It contextualizes the evolution of therapy from autologous hematopoietic stem cell transplants to engineered ex vivo and in vivo modalities, and it highlights how regulatory frameworks and early reimbursement dialogues are influencing trial design and commercial planning. The introduction also outlines the critical intersections between patient advocacy, specialized treatment centers, and academic research networks that will shape adoption pathways over the coming years.

By establishing this foundation, readers will be better equipped to interpret subsequent sections that analyze technological differentiation, payer engagement, regional delivery infrastructure, and company strategies. The goal is to present an integrated starting point that informs clinical decision-making, strategic partnerships, and investment priorities without presupposing a single adoption trajectory.

How recent technical advances, regulatory clarity, and integrated care innovations are shifting sickle cell treatment from symptomatic care toward durable genetic transformation

The landscape for treating sickle cell disease has shifted from incremental symptomatic care toward potentially transformative genetic interventions that reframe long-term clinical expectations. Advances in editing accuracy, vector design, and conditioning regimens have reduced historical barriers to efficacy and safety, prompting a recalibration of R&D priorities and care models. Concurrently, improvements in cell-manufacturing logistics and decentralized care pathways are enabling new approaches to patient throughput while preserving stringent quality controls.

Scientific progress has been complemented by regulatory clarity in key regions, which has encouraged more robust comparative trial designs and earlier engagement between developers and payers. This regulatory momentum, in turn, has accelerated collaborations between specialized treatment centers and industry partners to pilot end-to-end programs that integrate patient identification, enrollment, and long-term follow-up. As a result, the ecosystem is shifting from isolated clinical demonstrations to coordinated networks that can support broader, systematic adoption.

Clinically, the focus is gravitating toward durable clinical benefit, patient-centered outcomes, and safety profiles that are acceptable in both adult and pediatric populations. These priorities are driving cross-disciplinary investments in biomarker development, registry expansion, and health economics initiatives to demonstrate value. Taken together, these transformative shifts signal a maturing field where scientific promise is increasingly matched by pragmatic efforts to establish sustainable care and reimbursement models.

Assessing the practical operational and strategic consequences of 2025 tariff changes on cross-border sourcing, manufacturing resilience, and program continuity for gene therapies

Policy changes and tariff adjustments introduced in 2025 have added a new layer of complexity to cross-border procurement and supply chain planning for advanced biologics, including gene therapy reagents and cell-processing equipment. These trade measures have affected the cost structure and logistical calculus for manufacturers that rely on globalized sourcing of vectors, reagents, and specialized disposables. As a result, companies are reassessing supply-chain redundancy and nearshoring strategies to protect program timelines and quality oversight.

In response, many program leaders are intensifying supplier qualification processes and expanding dual-sourcing agreements to mitigate disruption risks. They are also accelerating investments in regional manufacturing capabilities and modular production platforms that can be deployed closer to clinical sites. This reorientation supports shorter lead times and reduces exposure to tariff volatility, while preserving sterile-chain integrity and regulatory compliance.

Operationally, clinicians and treatment centers are collaborating more closely with manufacturers to align scheduling windows and manage inventory buffers tied to domestic customs workflows. At the same time, payers and procurement officers are scrutinizing total cost of care and supply risk, prompting earlier price and access discussions. The net effect is a pragmatic repositioning of commercial and clinical strategies to maintain program resilience in the face of trade-related headwinds.

Deep segmentation-driven guidance linking treatment model, editing platform, patient demographics, severity profiles, payer mix, and delivery channel to commercialization strategy

Segmentation analysis provides a multidimensional lens through which therapeutic developers and health systems can prioritize investments and design differentiated value propositions. Based on Treatment Model, the dichotomy between Allogeneic and Autologous approaches informs manufacturing complexity, conditioning requirements, and logistics for donor selection versus individualized cell handling. Based on Modification Technology, distinctions among Base Editing, CRISPR/Cas9, Lentiviral Vector, and Zinc Finger Nuclease influence the narrative around precision, off-target risk, and the need for vector or editing platform-specific quality controls. Based on Patient Age, considerations differ for Adult and Pediatric populations with respect to conditioning tolerance, long-term safety surveillance, and ethical imperatives for early intervention. Based on Severity, approaches tailored to Moderate versus Severe disease must balance risk tolerance against potential clinical benefit, determining eligibility criteria and trial endpoints. Based on Payer Category, the dynamics among Government, Out Of Pocket, and Private payers shape reimbursement pathways, prior authorization protocols, and affordability programs. Based on Distribution Channel, delivery through Hospital versus Specialty Treatment Center has implications for credentialing, multidisciplinary care coordination, and how centers capture long-term outcome data.

Integrating these segmentation axes reveals nuanced opportunities for therapeutic differentiation. For example, a platform with a favorable safety profile that targets pediatric severe phenotypes may prioritize specialty treatment centers for early adoption and cultivate government and private payer dialogues focused on long-term outcome data. Conversely, treatments that rely on established lentiviral processes may lean into hospital networks with existing hematopoietic stem cell transplant infrastructure to scale capacity. Strategic plans that explicitly map technology attributes to patient demographics, disease severity, payer mix, and delivery channels will be better positioned to anticipate operational bottlenecks and accelerate patient access.

Comparative regional dynamics and infrastructure realities shaping clinical adoption, reimbursement engagement, and delivery models across global geographies

Regional dynamics materially influence the clinical and commercial trajectory of gene therapies for sickle cell disease, with distinct regulatory, infrastructural, and payer considerations across major geographies. In the Americas, established centers of excellence and active patient advocacy groups create fertile ground for early clinical adoption, while fragmented payer landscapes necessitate tailored reimbursement strategies and multi-stakeholder value narratives. Europe, Middle East & Africa presents a heterogeneous regulatory and delivery environment where centralized regulatory mechanisms coexist with diverse national payer systems, encouraging adaptive market-entry models and regional manufacturing partnerships. Asia-Pacific features a mix of rapidly expanding clinical trial capacity, growing investments in cell and gene therapy manufacturing, and variable reimbursement maturity that make phased, region-specific commercialization plans essential.

In all regions, the availability of specialized treatment centers, the density of experienced transplant teams, and the maturity of post-therapy registries determine practical access pathways. Additionally, regional differences in newborn screening programs, genetic counseling infrastructure, and public health priorities affect patient identification and recruitment strategies. Cross-border collaborations, technology transfer agreements, and local training programs are proving effective in addressing workforce constraints and accelerating the safe rollout of complex therapies.

Understanding these regional nuances allows sponsors and health system planners to align clinical development with scalable delivery models and payer engagement strategies that reflect local regulatory expectations and infrastructure realities.

Mapping the strategic behaviors of leading developers, manufacturing partners, and service providers that combine scientific differentiation with operational scale and payer engagement

Company strategies demonstrate a spectrum of approaches as developers and service providers align scientific capabilities with operational execution. Several leading biotechnology companies and established cell therapy manufacturers are pursuing differentiated pathways that emphasize specific editing platforms, vector expertise, or allogeneic manufacturing to address scalability and repeatability. Others are concentrating on clinical programs that prioritize pediatric indications or severe phenotypes where the potential for pronounced clinical benefit can strengthen reimbursement narratives.

Partnership models are increasingly common, pairing platform owners with contract development and manufacturing organizations to accelerate capacity expansion and reduce time-to-clinic risk. In parallel, collaborations between industry stakeholders and specialized treatment centers help operationalize care pathways, standardize safety monitoring, and aggregate long-term outcomes. Investors and strategic partners are also supporting companies that demonstrate robust quality systems, scalable supply chains, and credible plans for long-term patient follow-up.

Service providers that offer end-to-end logistics, cryopreservation, vector manufacturing, or long-term registry management are becoming essential components of the ecosystem. Their role is particularly pronounced for sponsors seeking to decouple clinical execution from in-house manufacturing complexities while preserving regulatory compliance. The evolving competitive landscape rewards entities that can combine scientific differentiation with demonstrated operational rigor and constructive payer engagement.

Actionable strategic moves for sponsors and health system leaders to secure clinical success, resilient operations, and payer-aligned evidence for durable gene therapies

Industry leaders should adopt a multitrack strategy that balances near-term clinical execution with investments in scalable operations and payer-facing evidence generation. First, prioritize robust safety and durability endpoints in trial design and expand registry participation to ensure longitudinal data capture that addresses payer and regulatory concerns. Simultaneously, cultivate partnerships with specialized treatment centers and regional manufacturing partners to create redundant, quality-assured supply chains that mitigate cross-border disruptions and tariff-related risks.

Second, tailor value communication to specific payer audiences by producing clear, mechanism-linked outcomes evidence and patient-centered metrics. Engage government, private, and out-of-pocket payer representatives early to co-design reimbursement pathways and outcomes-based contracting pilots where feasible. Third, invest in workforce training and credentialing programs for hospitals and specialty centers to ensure standardized delivery and post-therapy surveillance, thereby reducing variability in real-world outcomes.

Finally, pursue flexible commercial models that combine traditional pricing approaches with performance-linked arrangements and patient-support solutions. Build internal capabilities for health economics and outcomes research to quantify comparative value propositions and to inform payer negotiations. By implementing these measures, organizations will strengthen their clinical programs, secure more resilient supply chains, and create more credible value stories for diverse stakeholders.

Methodological transparency describing expert interviews, clinical and regulatory document synthesis, and triangulated evidence used to derive operationally relevant insights

The research approach combined qualitative and quantitative techniques to produce a rigorous analysis of clinical, operational, and policy dimensions. Primary research included structured interviews with clinical investigators, treatment center administrators, regulatory advisors, and payer representatives to capture real-world operational constraints and decision criteria. Secondary sources included peer-reviewed literature, clinicaltrials.gov listings, regulatory guidance documents, and industry white papers to contextualize clinical endpoints, safety signals, and regulatory precedents.

Data synthesis relied on triangulating insights from trial protocols, published safety and efficacy reports, and expert interviews to surface consistent themes and divergences. Supply-chain and tariff impact assessments were informed by customs documentation, logistics provider interviews, and manufacturer disclosures regarding sourcing strategies. The methodology also incorporated qualitative scenario mapping to explore plausible operational responses to regulatory shifts, payer engagement outcomes, and manufacturing contingencies.

To ensure reliability, findings were validated through follow-up discussions with select clinical and payer stakeholders and reviewed against the most recent regulatory guidelines. The resultant analysis emphasizes transparency about evidence sources and interpretive boundaries while offering practical recommendations grounded in observed practice and stakeholder priorities.

Concluding synthesis emphasizing the interplay of scientific progress, operational readiness, and multi-stakeholder evidence generation required for sustained therapeutic impact

Gene therapy for sickle cell disease is advancing into a stage where technical viability, clinical promise, and system-level readiness must coalesce to deliver meaningful patient benefit. Scientific innovation has lowered some historical technical barriers, but practical success will depend on coordinated investments in manufacturing resilience, clinician training, payer engagement, and long-term outcome capture. Stakeholders who proactively address these operational and evidentiary imperatives will find the most direct path to sustained clinical impact and responsible commercialization.

The field's trajectory suggests a shift from isolated clinical proof points to integrated programs that connect therapeutic platforms with delivery networks, payers, and patient communities. This shift requires transparent data-sharing agreements, pragmatic reimbursement dialogues, and iterative learning from early adoption pilots. Ultimately, the combination of robust clinical evidence, credible operational execution, and constructive payer partnerships will determine whether gene therapies for sickle cell disease deliver on their promise at scale.

As the ecosystem matures, continuous stakeholder alignment and adaptive strategies will remain essential. Organizations that marry scientific rigor with operational discipline and early payer-focused evidence generation will be best positioned to translate technological potential into durable patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Therapy for Sickle Cell Disease Market, by Treatment Model

  • 8.1. Allogeneic
  • 8.2. Autologous

9. Gene Therapy for Sickle Cell Disease Market, by Modification Technology

  • 9.1. Base Editing
  • 9.2. Cripr/Cas9
  • 9.3. Lentiviral Vector
  • 9.4. Zinc Finger Nuclease

10. Gene Therapy for Sickle Cell Disease Market, by Severity

  • 10.1. Moderate
  • 10.2. Severe

11. Gene Therapy for Sickle Cell Disease Market, by Payer Category

  • 11.1. Government
  • 11.2. Out Of Pocket
  • 11.3. Private

12. Gene Therapy for Sickle Cell Disease Market, by Patient Age

  • 12.1. Adult
  • 12.2. Pediatric

13. Gene Therapy for Sickle Cell Disease Market, by Distribution Channel

  • 13.1. Hospital
  • 13.2. Specialty Treatment Center

14. Gene Therapy for Sickle Cell Disease Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gene Therapy for Sickle Cell Disease Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gene Therapy for Sickle Cell Disease Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Gene Therapy for Sickle Cell Disease Market

18. China Gene Therapy for Sickle Cell Disease Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agios Pharmaceuticals, Inc.
  • 19.6. Beam Therapeutics, Inc.
  • 19.7. Bluebird Bio, Inc.
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. CRISPR Therapeutics AG
  • 19.10. Editas Medicine, Inc.
  • 19.11. EditForce, Inc.
  • 19.12. Emmaus Life Sciences, Inc.
  • 19.13. F. Hoffmann-La Roche Ltd.
  • 19.14. Fulcrum Therapeutics, Inc.
  • 19.15. Global Blood Therapeutics, Inc.
  • 19.16. Graphite Bio, Inc.
  • 19.17. Homology Medicines, Inc.
  • 19.18. Imara, Inc.
  • 19.19. Incyte Corporation
  • 19.20. Intellia Therapeutics, Inc.
  • 19.21. JCR Pharmaceuticals Co., Ltd.
  • 19.22. Magenta Therapeutics, Inc.
  • 19.23. Novartis AG
  • 19.24. Pfizer Inc.
  • 19.25. Precision BioSciences, Inc.
  • 19.26. Sangamo Therapeutics, Inc.
  • 19.27. Sanofi S.A.
  • 19.28. Vertex Pharmaceuticals Incorporated
  • 19.29. Vifor Pharma AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 144. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)